Cargando…

Suppression of Platelet-Derived Growth Factor Receptor-Alpha Overcomes Resistance to Trastuzumab through STAT3-Dependent IL-6 Reduction in HER2-Positive Breast Cancer Cells

Platelet-derived growth factor receptor (PDGFR) plays an essential role in the proliferation and invasion of malignant cancer cells. However, the functional role of PDGFR alpha (PDGFRA) in HER2-positive (HER2+) breast cancer has not been fully clarified yet. Thus, the objective of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sangmin, Kim, Hyungjoo, Jeong, Yisun, You, Daeun, Yoon, Sun Young, Lo, Eunji, Nam, Seok Jin, Lee, Jeong Eon, Kim, Seok Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045855/ https://www.ncbi.nlm.nih.gov/pubmed/36979654 http://dx.doi.org/10.3390/biomedicines11030675

Ejemplares similares

Tumorigenicity of EGFR- and/or HER2-Positive Breast Cancers Is Mediated by Recruitment of Tumor-Associated Macrophages
por: You, Daeun, et al.
Publicado: (2023)

Entelon(®) (Vitis vinifera Seed Extract) Prevents Cancer Metastasis via the Downregulation of Interleukin-1 Alpha in Triple-Negative Breast Cancer Cells
por: You, Daeun, et al.
Publicado: (2021)

Celastrol attenuates the inflammatory response by inhibiting IL-1β expression in triple-negative breast cancer cells
por: You, Daeun, et al.
Publicado: (2021)

Inhibition of platelet-derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor α positive breast cancer
por: Kim, Sangmin, et al.
Publicado: (2021)

Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction
por: Jeon, Myeongjin, et al.
Publicado: (2016)

Berberine Suppresses Fibronectin Expression through Inhibition of c-Jun Phosphorylation in Breast Cancer Cells
por: Jeong, Yisun, et al.
Publicado: (2018)

Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells
por: You, Daeun, et al.
Publicado: (2017)

A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells
por: Kim, Sangmin, et al.
Publicado: (2012)

Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase
por: Han, Jeonghun, et al.
Publicado: (2019)

Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer
por: Kim, Nalee, et al.
Publicado: (2023)

Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
por: Park, Soeun, et al.
Publicado: (2022)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway
por: Kim, Sangmin, et al.
Publicado: (2015)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
por: Luque-Cabal, María, et al.
Publicado: (2016)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer
por: Park, Woong Ki, et al.
Publicado: (2023)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
por: Mitani, Seiichiro, et al.
Publicado: (2020)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
por: Kim, Tae-Hwan, et al.
Publicado: (2021)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Berberine Suppresses TNF-α-induced MMP-9 and Cell Invasion through Inhibition of AP-1 Activity in MDA-MB-231 Human Breast Cancer Cells
por: Kim, Sangmin, et al.
Publicado: (2008)

Role of secreted type I collagen derived from stromal cells in two breast cancer cell lines
por: KIM, SUNG HOON, et al.
Publicado: (2014)

The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer
por: Cufí, Sílvia, et al.
Publicado: (2013)

Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
por: Nunes, Toni, et al.
Publicado: (2019)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

Psoriasis Induced by Trastuzumab (Herceptin®)
por: Kim, Dae Hun, et al.
Publicado: (2013)

Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
por: Lavaud, Pernelle, et al.
Publicado: (2014)

Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728
por: Irie, Hiroki, et al.
Publicado: (2020)

Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment
por: Kwon, Hyun Jung, et al.
Publicado: (2023)

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer
por: Bae, Soo Youn, et al.
Publicado: (2015)

STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer
por: Wang, Lei, et al.
Publicado: (2018)

Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells
por: DiScala, Molly, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3dpjotq8h3ioa0e39t0jn73m55